<DOC>
	<DOCNO>NCT02817659</DOCNO>
	<brief_summary>To understand tolerability glucagon .</brief_summary>
	<brief_title>To Determine Tolerability Glucagon Infusion Obese Subjects</brief_title>
	<detailed_description>To determine tolerability glucagon infusion administer escalate step-wise manner healthy obese subject</detailed_description>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Age 1855 year , inclusive 2 . BMI ≥27 ≤40 kg/m2 3 . Stable body weight 3 month ( selfreported loss/gain &lt; 5 % ) 4 . Subject judge nondiabetic good health basis medical history , physical examination , electrocardiogram , routine laboratory data 5 . Subject understands procedure agree participate study program give write informed consent , willing comply trial restriction 6 . Subject willing avoid alcohol consumption 48 hour prior inpatient study visit 7 . Subject willing avoid consumption caffeine caffeinated beverage 24 hour prior inpatient study visit 8 . Subject willing avoid strenuous physical activity 72 hour prior inpatient study visit 9 . Female subject child bear potential must willing use acceptable birth control study participation ( oral contraceptive , intrauterine device , implant injectable contraceptive , abstinence ) . 1 . Treatment medication know significantly impact body weight ( e.g. , weight loss medication , atypical antipsychotic ) within 3 month prior screen except stable physiological hormone replacement therapy ( i.e. , thyroid hormone , estrogen ) 2 . History bariatric surgery 3 . Current liver , renal , pulmonary , cardiac , oncologic , metabolic , gastrointestinal hematologic disease Investigator believe clinically significant , include : 1 . Liver disease liver injury indicate abnormal liver function test ( aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase , serum bilirubin ) &gt; 3 × upper limit normal ( ULN ) , history hepatic cirrhosis 2 . History presence impair renal function indicate estimate glomerular filtration rate &lt; 60 ml/hr urine albumintocreatinine ratio &gt; 35 mg/mmol 3 . Significant cardiovascular disease , include Class III great congestive heart failure ( CHF ) , coronary artery disease , second degree great heart block , clinically significant arrhythmia ; baseline second degree great heart block prolong QT syndrome ( QTc interval ≥ 470 msec ) ; major cardiovascular event within last 3 year ( include myocardial infarction , transient ischemic attack [ TIA ] , cerebrovascular accident [ CVA ] , angina , hospitalization due CHF , transient ischemic attack ( TIA ) , CVA ) 4 . Metabolic , endocrine disorder , include diagnosis type 1 type 2 diabetes mellitus [ HbA1c ≥6.5 % ] ) , inadequately treat hyperthyroidism ( thyroid stimulate hormone [ TSH ] normal range ) hypothyroidism ( TSH upper limit normal symptomatic TSH &gt; 10 U/mL ) , Cushing syndrome , Addison 's disease , hypogonadism , genetic disorder link obesity 5 . History irritable bowel disease , recurrent nausea vomit 6 . Anemia ( hemoglobin &lt; 12 g/dl men , &lt; 11 g/dl woman ) 4 . Selfreported history hepatitis B , hepatitis C , HIV 5 . History recurrent sleep disturbance and/or prone sleep disturbance base lifestyle employment ( e.g. , variable work schedule , overnight shift work , etc . ) 6 . Diagnosis sleep apnea without use ( continuous positive airway pressure ) 7 . Major surgery within last 3 month 8 . Blood donation within 4 week prior screen visit 9 . Participation another investigational trial within 4 week prior screen visit . The 4 week window derive date last trial medication and/or blood collection previous trial and/or adverse event ( AE ) relate trial drug screen visit current trial . 10 . Illicit drug abuse use nicotinecontaining product within 3 month prior screen visit 11 . Poor intravenous access 12 . Blood pressure le 100/50 mm Hg great equal 160/100 mm Hg screen visit 13 . Heart rate great equal 100 beats/min screen visit 14 . Fasting plasma glucose &lt; 60 mg/dL ≥126 mg/dL screen visit 15 . Translational Research Institute ( TRI ) staff member immediate relative TRI staff member , directly involve study 16 . History illness condition , opinion study investigator , might confound result study pose additional risk subject study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glucagon</keyword>
</DOC>